-+ 0.00%
-+ 0.00%
-+ 0.00%

Agenus prices oversubscribed private placement raising USD 85 million upfront, up to USD 340 million with warrants

PUBT·07/13/2026 10:32:10
Listen to the news
Agenus prices oversubscribed private placement raising USD 85 million upfront, up to USD 340 million with warrants
  • Agenus priced an oversubscribed private placement for USD 85 million upfront gross proceeds, with potential total gross proceeds up to USD 340 million.
  • Deal includes 23,035,227 common shares or pre-funded warrants, with Series A warrants for 21,144,277 shares at USD 4.02.
  • Series B warrants cover 33,797,214 shares at USD 5.03, exercisable immediately, adding up to USD 255 million if fully exercised.
  • Proceeds earmarked for the planned registrational Phase 3 ROBBIN trial of neoadjuvant BOT+BAL in MSS colon cancer, with runway through 2031 on full exercise.
  • Program shift includes ending financial support for the BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-301414), on July 13, 2026, and is solely responsible for the information contained therein.